ALASKA MEDICAID
Prior Authorization Criteria

Auvelity®
(dextromethorophan HBr & bupropion HCl)

FDA INDICATIONS AND USAGE[1]
Auvelity® is combination of dextromethorphan, an uncompetitive N-methyl D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, and bupropion, an aminoketone and CYP450 2D6 inhibitor, indicated for the treatment of major depressive disorder (MDD) in adults.

APPROVAL CRITERIA[1,2,3]

1. Patient meets FDA labeled age **AND**;
2. Patient has the diagnosis of major depressive disorder **AND**;
3. Patient has tried and failed a minimum of two different antidepressants for a minimum of 60 days at therapeutic dose levels

DENIAL CRITERIA [1,2]

1. Failure to meet approval criteria **OR**;
2. Patient has been diagnosed with a seizure disorder **OR**;
3. Patient has a current or prior diagnosis of anorexia nervosa or bulimia nervosa **OR**;
4. Auvelity® will be taken within 14 days of treatment with a monoamine oxidase inhibitor (MAOI) **OR;**
5. Patient has severe hepatic or renal impairment

CAUTIONS[1]

- May cause fetal harm.
- May cause or worsen hypertension
- As with other antidepressants, dextromethorphan/bupropion carries a boxed warning relating to risk of suicidal thoughts and behaviors.

DURATION OF APPROVAL

- Initial Approval: 3 months
- Renewal: up to 12 months

QUANTITY LIMIT

- 68 tablets within 34 days/max dose 2 tablets per day

REFERENCES / FOOTNOTES:

1. Auvelity (dextromethorphan HBR/bupropion HCl) [prescribing information]. New York, NY: Axsome Therapeutics; August 2024
2. Tabuteau H, Jones A, Anderson A, et al. Effect of AXS-05 (Dextromethorphan-Bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry. 2022 Jul;179(7):490-499.
3. American Psychological Association. Clinical practice guideline for the treatment of depression across three age cohorts. 2019. Available at: https://www.apa.org/depression-guideline.